Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q3381667> ?p ?o }
Showing triples 1 to 35 of
35
with 100 triples per page.
- Q3381667 subject Q8503492.
- Q3381667 abstract "SAV001-H is the first preventive HIV vaccine using a killed or "dead version" of HIV-1 virus. The vaccine is developed by Dr. Chil-Yong Kang and his research team at Western University’s Schulich School of Medicine & Dentistry in Canada. The result of the US FDA Phase I clinical trial completed in August 2013 showed no serious adverse effects in 33 participants.".
- Q3381667 thumbnail Various_approaches_for_HIV_vaccine_development.jpg?width=300.
- Q3381667 wikiPageExternalLink NCT01546818?spons=%22Sumagen%22&spons_ex=Y&rank=1.
- Q3381667 wikiPageExternalLink killhivnow.org.
- Q3381667 wikiPageExternalLink eng.
- Q3381667 wikiPageExternalLink US20110014221?hl=ko&cl=en.
- Q3381667 wikiPageExternalLink sav001-hiv-vaccine-side-effects-adverse_n_2102593.html.
- Q3381667 wikiPageExternalLink IAVI_IAVI_REPORT_JAN-MAR_1999_ENG.pdf.
- Q3381667 wikiPageExternalLink www.schulich.uwo.ca.
- Q3381667 wikiPageExternalLink hosted_kang.html.
- Q3381667 wikiPageExternalLink aids_vaccine.htm.
- Q3381667 wikiPageExternalLink intro.htm.
- Q3381667 wikiPageWikiLink Q1129598.
- Q3381667 wikiPageWikiLink Q1142055.
- Q3381667 wikiPageWikiLink Q1144262.
- Q3381667 wikiPageWikiLink Q1351110.
- Q3381667 wikiPageWikiLink Q1479804.
- Q3381667 wikiPageWikiLink Q14875419.
- Q3381667 wikiPageWikiLink Q154869.
- Q3381667 wikiPageWikiLink Q182506.
- Q3381667 wikiPageWikiLink Q1890246.
- Q3381667 wikiPageWikiLink Q193529.
- Q3381667 wikiPageWikiLink Q200101.
- Q3381667 wikiPageWikiLink Q376266.
- Q3381667 wikiPageWikiLink Q424512.
- Q3381667 wikiPageWikiLink Q4596740.
- Q3381667 wikiPageWikiLink Q491503.
- Q3381667 wikiPageWikiLink Q655286.
- Q3381667 wikiPageWikiLink Q6853.
- Q3381667 wikiPageWikiLink Q7632279.
- Q3381667 wikiPageWikiLink Q8503492.
- Q3381667 comment "SAV001-H is the first preventive HIV vaccine using a killed or "dead version" of HIV-1 virus. The vaccine is developed by Dr. Chil-Yong Kang and his research team at Western University’s Schulich School of Medicine & Dentistry in Canada. The result of the US FDA Phase I clinical trial completed in August 2013 showed no serious adverse effects in 33 participants.".
- Q3381667 label "SAV001".
- Q3381667 depiction Various_approaches_for_HIV_vaccine_development.jpg.